Clinical trials recruiting in George Town, Malaysia

Phase breakdown

Conditions recruiting in George Town, Malaysia

Recruiting trials in George Town, Malaysia

• A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
  NCT07190248 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
  NCT06966700 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
  NCT06868277 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
  NCT06692738 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
  NCT06717698 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
  NCT06750094 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
  NCT06662786 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
  NCT05774951 · Phase: Phase 3 · Ages: 18 Years to 130 Years · Sex: All (male and female)
• A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
  NCT06492616 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
  NCT06077760 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
  NCT06008197 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
  NCT07361510 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
  NCT06452277 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
  NCT06219941 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
  NCT06120283 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
  NCT07492641 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
  NCT06531824 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
  NCT07064473 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
  NCT07190222 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
  NCT06765109 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
  NCT07085767 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
  NCT04613596 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
  NCT06757634 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
  NCT04686305 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• Randomised Evaluation of Sodium Dialysate Levels on Vascular Events
  NCT02823821 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female)
• Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo
  NCT07069829 · Phase: Not specified · Ages: 30 Years to 80 Years · Sex: All (male and female)
• Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
  NCT05315700 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• The Osteoporotic Fracture Classification-based Scoring System for Treatment Decision in Thoracolumbar Osteoporotic Fractures
  NCT07027306 · Phase: Not specified · Ages: 50 Years and older · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in George Town, Malaysia?

28 recruiting trials have at least one study site in George Town, Malaysia.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.